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Abstract: We here propose an updated concept of stem cells (SCs), with an emphasis on neural stem cells (NSCs). The 
conventional view, which has touched principally on the essential property of lineage multipotency (e.g., the ability   
of NSCs to differentiate into all neural cells), should be broadened to include the emerging recognition of biofunctional 
multipotency of SCs to mediate systemic homeostasis, evidenced in NSCs in particular by the secretion of neurotrophic 
factors. Under this new conceptual context and taking the NSC as a leading example, one may begin to appreciate and 
seek the “logic” behind the wide range of molecular tactics the NSC appears to serve at successive developmental stages 
as it integrates into and prepares, modifies, and guides the surrounding CNS micro- and macro-environment towards  
the formation and self-maintenance of a functioning adult nervous system. We suggest that embracing this view of the 
“multipotency” of the SCs is pivotal for correctly, efficiently, and optimally exploiting stem cell biology for therapeutic 
applications, including reconstitution of a dysfunctional CNS. 
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BACKGROUND 
  Along with refinement of our understanding on the biology 
and translational potential of neural stem cells (NSCs)   
[1-6], there has been an increasingly appreciated paradigm 
shift regarding how the adult mammalian central nervous 
system (CNS) could be repaired for functional restoration. 
The long-standing dogma that the adult CNS was immutable 
to anatomical and functional repair was challenged by an 
unambiguous demonstration that cells derived from the CNS 
from a variety of structures and at different developmental 
stages, including adulthood, possess stem-like properties. 
NSCs are primordial and uncommitted cells that have been 
believed to give rise to the vast array of more specialized 
cells of the CNS. They are operationally defined by their 
abilities (1) to differentiate into cells of all neural lineages 
(i.e. neurons of multiple subtypes, oligodendroglia, and   
astroglia) in multiple regional and developmental contexts 
(i.e., to be multipotent); (2) to self-renew (i.e., to give rise also  
to new NSCs with similar potential); (3) to migrate and 
populate developing and/or degenerating CNS regions; and  
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(4) to have biofunctional multipotency to mediate systemic 
homeostasis through capacities such as production of trophic 
factors, formation of gap junctions, etc. [7,8]. Since monoclonal 
derivation of progeny is obligatory to the definition of NSC: 
that is, a single cell must possess all the aforementioned   
attributes, which suggests the ready availability of NSCs, 
many studies, including ours, in the past two decades,   
provided hope that the use of NSCs might circumvent some 
limitations of presently available graft material and gene trans- 
fer vehicles and make feasible a broader range of therapeutic 
strategies. This significant advance has led neurobiologists to 
speculate how such phenomena might be further harnessed 
for both therapeutic advantage and for better understanding 
of developmental neurobiology mechanisms. 
  Most studies, to date, are focused principally on exploring 
the biologically most apparent features of NSCs in   
comparison to existing gene therapy and cell transplantation 
strategies. For this purpose, NSCs, with their homogeneous 
and well-defined neural differentiation capacity, have been 
pursued primarily as a modality that could replace dead or 
degenerating neural cells in a wide variety of neurological 
diseases and trauma. For certain pathological models of the 
brain, NSCs and their progeny not only could integrate with 
host tissue at their site of implantation [9-11], but also could 
interact with distant brain tissue via migration in response to Functional Multipotency of Stem Cells  Current Neuropharmacology, 2011, Vol. 9, No. 4    575 
chemical cues in the host [12-15]. The responsiveness of 
NSCs to microenvironmental cues in the surrounding CNS 
tissue provides them with a unique trait distinguishing them 
from fetal brain/spinal cord tissue and non-neural cells (e.g., 
fibroblasts or mesenchymal stromal stem cells [MSCs]), as 
well as from most viral vectors and protein infusion devices 
for gene delivery. For example, haematopoietic cells could 
not efficiently cross the blood–brain barrier and integrate 
throughout the CNS as effectively as NSCs. In addition, 
NSCs are able to “sense” the presence of degenerating neural 
tissue [13,14,16-18]. Conversely, effective replacement of 
dying or dysfunctional neurons by NSCs in the adult CNS, 
an ideal hypothesis the field initially entertained, has been 
proven to be a much more challenging endeavor, though in a 
few experimental models of neurodegeneration such NSC-
based cell substitution appeared to be feasible in replacing 
dead oligodendrocytes [9,19]. We therefore have discussed 
here the biological perspectives of epigenetic and genetic 
features of rodent (in particular, murine) and human neural 
stem cells regarding their capacity to produce neurotrophic 
factors (NTFs). Also included are views of investigators in 
the field on how to modulate and/or augment the homeostatic 
function of NSCs. Finally we summarize our current 
thoughts about the critical roles that NSCs may play in   
designs for improved regimens of NTF delivery regarding 
neural repair and pathology correction. 
NEUROTROPHIC FACTORS AND NEURAL STEM 
CELLS 
  Because NSCs are dynamic developmental entities their 
therapeutic potential has been studied primarily via strategies 
devised to realize desirable neural phenotypic differentiations. 
Much less recognized and appreciated is the fact that these 
developmental cells, by innate biology, produce neurotrophic 
factors that influence the growth and well-being of their   
own and surrounding tissues via  autocrine and paracrine 
mechanisms. Efforts to understand this more recently   
recognized perspective of stem cell biology were first   
triggered by the observation that undifferentiated donor 
NSCs could exert marked neuroprotection to the spinal cord 
following traumatic injury, engendering a speculation that 
NSCs and other stem cells may have inherent capability to 
synthesize trophic factors [20]. Considerable research   
endeavors have since taken place to seek beneficial impact of 
stem cells (e.g., NSCs, MSCs, and embryonic stem cells 
[ESCs]) that are mediated mainly through soluble trophic 
factors and other cytokines that enable the body to reestablish 
homeostasis after pathologic and traumatic insults,   
inflammation, and tissue infarction or degeneration [21-24]. 
In this article, based on data mainly derived from studies on 
traumatic spinal cord injury (SCI), we seek to establish   
conceptually the biological principles of trophic factor   
delivery by stem cells as a novel approach to new therapeutic 
strategies based on developmental mechanisms [7]. For this 
goal, we have expanded the conceptual scope of tropic   
factors to include the following categories of molecules. 
  By our definition, neurotrophic factors, here including 
classic neurotrophins, are groups of naturally occurring   
substances that support neural cell survival, proliferation, 
migration, differentiation, growth, and function [25]. They 
are usually proteins or simpler peptides, and are essential 
regulating and signaling molecules for cell development and 
function. Neurotrophic factors contribute to neurogenesis, 
and are critical in shaping neural network structure and 
physiological processes such as learning, memory formation, 
and sensorimotor function [26]. Some neurotrophic factors, 
conversely, can be directly involved in pathological processes 
[25],  via  effects on synaptic biology, dynamics of neuro-
transmitter release and synaptic efficacy, whereas others act 
through secondary messengers and various kinases [27].  
  Listed below are the six biological families of neuro- 
trophic factors that directly impact stem cell development, 
and are expressed by natural or bioengineered stem cells. 1. 
Classic neurotrophins that comprise nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3), and neurotrophin-4 (NT-4); 2. The transforming 
growth factor (TGF)-beta family, represented by glial cell 
line-derived neurotrophic factor (GDNF) and the bone 
morphogenic proteins (BMPs); other members are neurturin, 
artemin, and persephin; 3. The cytokine growth factor fam-
ily, including ciliary neurotrophic factor (CNTF), leukemia 
inhibitory factor (LIF), and cardiotropin-1; 4. The epidermal 
growth factor (EGF) family, consisting of EGF, transforming 
growth factor-alpha (TGF-alpha), the neuregulins, and neural 
and thymus-derived activator for ErbB kinases (NTAK); 5. 
The insulin-like growth factors (IGFs), consisting of insulin-
like growth factor I (IGF-I) and IGF-II; and 6. The fibroblast 
growth factor (FGF) family, consisting of at least 24   
different proteins including acidic FGF (FGF 1) and basic 
FGF (FGF 2) [28,29].  
  For the purpose of this review, we focus our discussion 
only on the family of classic neurotrophins since all its 
members (i.e., NGF, BDNF, NT-3, and NT4/5) have been 
demonstrated to play critical roles in neuronal survival,   
differentiation, and/or function in neurotrauma settings [30]. 
The neurotrophins act by binding to receptor tyrosine kinases 
of the Trk families. NGF binds for tropomyosin-receptor-
kinase-A (TrkA), BDNF and NT-4/5 bind TrkB, and NT-3 
preferentially binds TrkC. Importantly, NT-3 up-regulates 
TrkC expression in NSCs and induces them to differentiate 
into neurons [31-33]. For example, Ad-TrkC can be   
constructed to express TrkC effectively in NSCs, enhancing 
NT-3-mediated neuronal differentiation, an approach that 
may offer additional strategies for treating neurotrauma [33]. 
Overexpression of TrkC in rat neural progenitor cells   
improves survival and reduces glial differentiation of donor 
cells in the intact spinal cord [34]. Neurotrophin-mediated 
Trk signaling plays an essential, cell-autonomous role in 
regulating the proliferation and differentiation of embryonic 
cortical precursors and thus controls cortical development at 
early stages [35]. Multiple alternatively spliced isoforms 
have been observed for TrkA, TrkB, and TrkC, especially in 
non-neuronal cells [31,36-38]. Some of these isoforms lack 
the cytoplasmic tyrosine kinase domain, but retain selective 
signaling and may inhibit neurite outgrowth [37,39-41]. 
However, brain-derived neurotrophic factor (BDNF) has 
proliferative effects on NSCs through the truncated TRK-B 
receptor [42]. Neurotrophins also bind to p75NTR. Activation 
of this receptor may cause cell death rather than survival, as 
p75NTR
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pilocarpine-induced seizures compared to wild-type [43,44]. 
Interestingly, the p75 neurotrophin receptor is also involved 
in proliferation of undifferentiated mouse ESCs, and   
becomes down-regulated upon ES cell differentiation [45]. 
NT-3 improves the neural differentiation of skin-derived 
precursors (SKPs) induced by retinoic acid (RA) through a 
p75NTR-dependent signaling pathway [46,47]. In the   
following sections, we will discuss how a novel concept of 
using prototype or engineered NSCs to deliver therapeutic 
neurotrophic factors was developed, based on data collected 
from SCI investigations, and how this concept has   
subsequently been used to guide administration of neuro- 
trophic factors to treat or investigate representative neuro-
logical disorders such as SCI, Alzheimer's disease (AD) and 
amyotrophic lateral sclerosis (ALS). 
ADMINISTRATION OF NEUROTROPHIC FACTORS 
FOR TREATING SCI 
  The pharmacological use of neurotrophic factors for SCI 
treatment has been tested primarily with two neurotrophins: 
BDNF and NT-3. Unlike peripheral nerve axons, which re-
generate well, the adult mammalian spinal cord appears to 
have an unsuccessful capacity for axonal regrowth [48,49]. 
Neurotrophic factors, when administered in appropriate 
physical and temporal gradients, have been shown to support 
axonal growth after peripheral nerve injury. In contrast,   
antagonizing these growth factors in the extracellular matrix 
impedes neurite outgrowth [50,51]. Due to these findings, 
plus the fact that molecules have been identified that can 
suppress axonal sprouting and regeneration in the CNS (e.g., 
the chondroitin sulfate proteoglycan [CSPG] molecules) 
[52,53], substantial experimental efforts have been given to 
enhance regeneration of the supraspinal descending axons 
through activating neurotrophic factor-mediated mechanisms 
that may overcome the growth inhibitory environment in the 
CNS [54-60]. Additional approaches include combinatorial 
tactics that comprise transplantation of progenitor cells into 
the lesion cavity with simultaneous administration of   
neurotrophic factors [61], or direct augmentation of key 
molecules of trophic factor-triggered signal transduction, 
such as raising intracellular cAMP levels pharmacologically 
[62,63]. Many of these studies report incremental improvement 
in axonal growth and/or motor behavior, projecting hope for 
advancing towards the ultimate goal of restoring function 
following clinical SCI.  
  As examples, several groups reported that BDNF can 
enhance growth of supraspinal motor axons into permissive 
growth milieus placed at sites of SCI. Both rubrospinal   
axons [64,65] and reticulospinal axons [66], descending   
networks that regulate spinal cord motor neural activities, 
regenerate in response to BDNF stimulation. Reversal   
of atrophy of neurons in the red nucleus, even one year   
after SCI, can occur after BDNF stimulation [67]. However, 
corticospinal tract (CST) axons did not respond to   
BDNF post-SCI, even though BDNF prevents the death of 
corticospinal neuronal cell bodies when directly applied to 
the cerebral cortex. This outcome has been attributed to the 
lack of BDNF receptor TrkB on CST fibers [68].  
  The ability of NT-3 treatment to promote regeneration of 
severed CST axons was also reported [69]. This triggered 
additional bioengineering initiatives to enhance the delivery 
efficiency of NT3. Subsequently, Grill and colleagues, 
adapting a gene therapy strategy, demonstrated that   
autologous fibroblasts genetically modified to secrete NT-3 
could be transplanted into the epicenter of experimental SCI 
to improve neural repair [70]. More recently, Tuszynski’s 
group at UCSD reported beneficial effects of artificially   
established NT-3 gradients using cell-based gene delivery, 
increasing axonal regeneration in experimental SCI [71]. 
Importantly, studies comparing the therapeutic effect on   
axonal growth of three different methods of replenishing 
neurotrophic factors (direct infusion, transplantation of   
unmodified cells, and transplantation of genetically   
engineered cells with enhanced secretory function) have   
reported favorable results with genetically modified cells [72]. 
These data support the notion that using cells to administer 
neurotrophic factors may offer clinically favorable   
pharmacodynamic properties due to the interactive capability 
of “these functional basic units of life” [71,72]. Therefore, 
donor cells such as NSCs, in particular, have become highly 
promising candidates for delivering NTFs due to their innate 
biology, which regulates molecule secretion in response to 
environmental changes in the nervous system [7]. 
  This viewpoint is further strengthened by observation of 
a therapeutic impact of endogenous NSCs on experimental 
SCI under the enhanced physical activity paradigm of reha-
bilitation that induced functional recovery. In some cases, 
there was a positive correlation between degrees of functional 
improvement and the number of nestin-expressing NSCs 
present in the post-lesion spinal cord [73-76], suggesting that 
NSC proliferation enhanced by exercise may help augment 
NTF production (see below for more details). Additional 
support comes from the facts that severe side effects of   
neurotrophic factors could be caused by conventional drug 
delivery regimens that lack biological feedback regulations, 
and by barriers imposed by the peptidergic structure of   
these trophic factors, which impair their penetration into the 
brain or spinal cord parenchyma, and therefore make their 
pharmaco-therapeutic properties difficult to evaluate [77].  
A NOVEL CONCEPT OF USING PROTOTYPE OR 
ENGINEERED NSCS TO DELIVER NEUROTROPHIC 
FACTORS: INSIGHTS FROM STUDIES OF   
ENDOGENOUS NSCS AND ACTIVITY-DEPENDENT   
RECOVERY FOLLOWING SCI 
  Endogenous NSCs in the spinal cord and their response 
to trauma: Mitotic activity has been known to persist in the 
adult mammalian spinal cord [78]. Weiss and colleagues 
found that the lumbosacral spinal cord normally produces the 
greatest number of multipotent cells, and the cervical cord 
the least [79]. Under most conditions, adult NSCs have   
astroglial characteristics and express glia fibrillary-associated 
protein (GFAP) [78], but retain the ability to undergo neuro-
genesis [80,81], and can give rise to functional neurons   
and glia in vitro and in vivo [82]. It has been shown that  
neurotrauma significantly increases the proliferative capacity 
of spinal cord NSCs. Ependymal zone cells that express low 
levels of nestin were found to be upregulated, increasing 
mitotic activity and generating glia, shortly after an injury  
to the dorsal funiculus of the spinal cord. If implanted in   
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capable of migrating and undergoing neurogenesis [81,83, 
84,85].  
  Ependymal and parenchymal neural progenitors were 
also reported to be activated in response to spinal cord trans-
action [86,87]. When isolated in vitro, they generate   
astrocytes and oligodendrocytes but few neurons. A fraction 
of ependymal zone cells possessing stem cell properties or 
oligodendrocyte progenitor cells in the parenchyma proliferate 
following compression and contusion injuries [84,88], and 
appeared to participate in repopulation of the injured areas, 
suggesting their potential participation in lesion repair 
[89,90]. This response of NSCs to the injury occurs rather 
rapidly; for instance, nestin was seen in ependymal cells as 
early as 1 day after minimal sharp instrument injury to the 
lateral columns [91]. This injury, however, did not supply a 
sufficient stimulus for ependymal zone cells to migrate to the 
lesion site. A relatively larger injury to the dorsal funiculus, 
by contrast, led to ependymal zone NSC migration from the 
central canal to the lesion site [82]. 
  Since brain NSCs have been reported to respond to   
external stimuli such as enhanced physical activity and   
exercises, by increasing their proliferation, differentiation 
and survival [92], an extension of that rationale is to ascertain 
whether physical activity and exercise could serve as an   
independent stimulus for endogenous NSC proliferation also 
in the adult spinal cord. We earlier hypothesized that a major 
function of proliferating NSCs in the adult mammalian CNS 
is the production of trophic factors and other homeostasis-
maintaining molecules that are essential for endogenous 
healing and plasticity processes in the spinal cord [93].  
Our published data suggest that physical activity may be 
beneficial partially by increasing proliferation of endogenous 
NSCs that produce neurotrophic factors such as GDNF and 
BDNF, which in turn mediate neuroplasticity and improve 
sensorimotor functions [74]. Conversely, the contribution of 
neurotrophic factors to exercise-induced functional recovery 
per se has been investigated extensively. Voluntary exercise 
induces an up-regulation of BDNF and NT3 mRNA and   
protein levels in the spinal cord [94]. Increased levels of 
BDNF-associated mRNA and protein levels near the injury 
site have also been reported following treadmill training or 
running [94]. Additionally, direct stimulation of hindlimb 
stepping was noted after intrathecal administration of BDNF 
[95]. Other factors related to BDNF activity, such as   
synapsin 1, NT-3 and cyclic AMP (cAMP) response element 
binding protein (CREB), are also elevated in response to 
post-injury exercise [96]. 
  Although injury alone may induce an increase in the levels 
of these neurotrophic agents [97], these astrocyte-based   
increases were transient (< 2 days after SCI), and thus,   
unlikely to facilitate later phase neuroplasticity or functional 
recovery. In contrast, animals that were exercised in the post-
injury period demonstrated prolonged elevation of these   
factors, which may offer a new therapeutic window for other 
interventions. There is currently no agreed-upon conclusion 
regarding the origin of exercise-enhanced BDNF expression 
despite numerous studies that implemented NSCs, astrocytes, 
neurons and blood-born cells as neurotrophin providers   
under varied situations [98]. Finally, the spinal cord's inherent 
regenerative potentials can also be directly stimulated by 
post-injury physical activity. Exercise has been shown to 
double the number of proliferative cells in the CNS [74,99] 
and to have additional benefits, such as enhanced long-term 
potentiation of post-synaptic efficiency [100]. 
  Overall, experimental outcomes suggest that synapse 
formation and maintenance can be activity-dependent (e.g., 
exercise-driven), largely operated by neurotrophins [101]. 
Such neurotrophic drives may not only promote birth of new 
neurons, but also facilitate oligodendrogenesis [102]. We 
therefore speculate that the amplitude of NSC-based release 
of neurotrophic factors could be further modified by physical 
activity-related rehabilitation modalities and specific   
pharmacological treatments augmenting NSC participation 
and their trophic factor production that, by mimicking   
developmental processes, augment reciprocal therapeutic 
relationships with surrounding cells and cue molecules [7].  
MECHANISMS THAT ENABLE THERAPEUTIC   
DELIVERY OF NEUROTROPHIC FACTORS FROM 
PROTOTYPE OR GENETICALLY ENGINEERED 
NSCS FOR SPINAL CORD REPAIR 
  It has been well recognized that NSCs have an innate 
ability to detect pathologic targets for trophic actions. We 
and other investigators previously described a critical feature 
of prototype NSCs that is distinct from non-NSC carriers of 
neurotrophin transgenes – the ability to detect pathological 
loci and adopt appropriate developmental initiatives toward 
customized trophic support or cell replacement [103,104]. 
These abilities were first suggested by experimental data   
that was derived from a clone of murine NSCs after their 
implantation into an adult rat spinal cord after segmental 
hemisection (i.e., open wound lesion), where the NSCs   
contibuted markedly to functional restoration [20]. Moreover, 
when NSCs of the same lineage were transplanted into   
adult mouse neocortex in which pyramidal neurons of a   
circumscribed region were induced experimentally to undergo 
apoptosis, they differentiated differently than when grafted 
into uninjured neocortex: they preferentially differentiated 
into pyramidal neurons, whereas these same NSCs yielded 
mostly glia in normally developed neocortex [103]. These 
data indicate that donor NSCs can respond to biological cues 
in normal and abnormal microenvironments, suggesting that 
NSCs spontaneously have mechanisms compensating for 
genetic [17,105] or acquired deficiencies [14]. Though the 
exact mechanisms regulating the capacity of NSCs to exert 
developmental functions in an adult microenvironment are 
still unknown, it is clear that when confronted with injury or 
other pathologic conditions, NSCs recapitulate certain of 
their developmental mechanisms [24,93,103]. 
  It is currently believed that the signals modifying   
exogenous and endogenous NSC production of trophic factors 
affect a complex group of mitogens and chemokines, trophic 
and tropic agents, plus adhesion and extracellular matrix 
molecules (i.e., common developmental signaling molecules), 
as well as chemotactic and angiogenic factors, activated   
microglia, inflammatory cells, invading macrophages and 
damaged neurons and glia (i.e., general inflammation-
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protection and repair in the post-mitotic environment of the 
adult CNS may require overcoming an insufficient supply   
of NSCs and endogenous neurotrophic factors. Hence,   
donor NSCs become attractive to consider as therapeutic 
supplements. However, exogenous prototype NSCs without 
engineered enhancements are vulnerable to same insults 
from secondary injury molecules as endogenous cells 
[20,106]. Therefore, we and our colleagues at the Langer 
Lab at MIT recently devised a novel chemical engineering 
approach to protect donor NSCs by applying antioxidant 
drug-releasing polymer film to alter the implantation milieu 
against neuroinflammation mediated by reactive nitrogen 
species (RNS). Our technology has been fruitful not only   
in enhancing the survival of exogenous NSCs but also in 
maintaining their capacity to produce neurotrophic factors 
such as GDNF and BDNF [107].  
APPLICATION OF NTFS OR NSCS TO TREAT   
NEURODEGENERATIVE DISEASES  
  As a consideration of translational initiatives beyond SCI, 
the following sections will briefly discuss the possibility of 
using NTFs and NSCs in treatment of neurodegenerative 
diseases, citing studies on Alzheimer’s Disease (AD) and 
amyotrophic lateral sclerosis (ALS) as representative   
examples. 
  The potential use of NGF, a member of the neurotrophin 
family, for AD therapy has been reviewed in detail [29]. NGF 
emerged as a candidate therapeutic molecule for neuronal 
degeneration soon after its discovery [111], due to its role as a 
vital survival factor for sensory and sympathetic neurons during 
development [112]. NGF also prevents both lesion-induced 
and spontaneous atrophy of basal forebrain cholinergic   
neurons, as well as ameliorating memory deficits in aged 
rats; both are hallmark therapeutic targets for AD [113-115]. 
In AD animal models NGF treatment reduced neuronal 
death, and simultaneously stimulated cholinergic neurons, 
despite exposure to a cohort of deleterious mechanisms that 
cause neuronal degeneration, including excitotoxicity, aging, 
and amyloid overproduction [116-122]. NGF treatment   
improved cognition in a variety of models of rodent memory 
dysfunction, and its neuroprotective actions have been   
also confirmed in non-human primate models [123-128]. 
Mechanistically, NGF activates Erk/MAP kinase to influence 
a number of growth and function-related intracellular   
pathways via TrkA receptors, and activates pro-survival gene 
expression and inhibits apoptosis via  the Akt pathways 
[127]. The studies to date validate the essential trophic   
impact of NGF on adult cholinergic neurons, and corroborate 
that NGF is needed (and produced) throughout life in the 
neocortex and hippocampus [128,129].  
  Therefore, if the expressions of p75 and TrkA receptors 
remain sufficient for NGF responsiveness, NGF delivery 
near degenerating cholinergic neurons appears to be an ap-
pealing clinical strategy [130-133]. However, effectively 
delivering NGF to the brain in humans remains a challenge, 
primarily because the NGF protein is too large to cross the 
blood brain barrier (BBB). Intra-ventricular infusion can 
bypass the BBB in animal models, but then, NGF spreads 
non-selectively in the CNS, resulting in unwanted side   
effects such as weight loss [134], sympathetic axon sprouting 
[135] and neuropathic pain related to Schwann cell invasion 
[136,137], despite effectiveness in the rescue of degenerating 
cholinergic neurons. The adverse effects were also observed 
in human trials [138]. Similar effects occurred in trials of 
patients with Parkinson’s disease when GDNF or BDNF 
were infused intraventricularly [139,140]. These side effects 
observed in clinical trials highlight the necessity to establish 
new approaches that can overcome certain ineffective   
aspects of direct NTF delivery that lacks feedback regulatory 
mechanisms. 
  ALS is a fatal neurodegenerative disease with a signature 
pathology of progressive motor neuron death in both the 
spinal cord and brain, which culminates in rapid loss of   
muscle function and eventual respiratory failure [141,142]. 
The only clinically available therapy to date is riluzole   
(Rilutek), which marginally extends survival by limiting 
excitotoxicity [143] and increasing neurotrophin release 
from astrocytes [144]. The majority of ALS cases are   
sporadic, whereas only 10% are familial (FALS) [145], 
among which 15-20% can be traced to point mutations in 
cytosolic Cu
2+/Zn
2+ superoxide dismutase 1 (SOD1) [146].  
  The rapid neuronal degeneration in ALS deems neuronal 
replacement and neuroprotection as valuable clinical   
approaches to treatment. Therefore, different types of progenitor 
or stem cells with capacity to produce NTFs have been tested 
in rodent models of ALS [147-151]; these include hNT   
neurons derived from the human teratocarcinoma cell line, 
mouse Sertoli cells [147,149], human umbilical cord blood 
cells [147,151], human [151], or mouse [148] bone marrow 
transplants, [152] and mouse or human NSCs [153,154].  
  Data in published studies suggests, at first glance, that the 
lineage or site of origin of NSCs may be responsible for 
some of the drastic differences in therapeutic efficacy. For 
instance, transplantation of human NSCs isolated from fetal 
forebrain (i.e., HFB2050) [14] into multiple loci of the spinal 
cord resulted in marked increase of life span in SOD1 
(G93A) mice [154], whereas neural progenitor cells (NPCs) 
derived from human cortex and spinal cord produced lesser 
results [155]. However, further analysis suggests that the 
NTF profiles of donor cells might have played a key role 
determining the therapeutic effect in rodent ALS models 
[154,156]. Prototype human NSCs (HFB2050) secrete a 
spectrum of NTFs, including BDNF and GDNF [14], whereas 
genetically engineered NPCs may produce high levels of one 
specific NTF only, which may not be adequate to counteract 
ALS pathophysiology that is triggered by multiple pathogenic 
pathways [141]. Likewise, direct expression of GDNF delivered 
by lentiviral vector transfection to the lumbar spinal cord 
showed no beneficial effects on motor neuron survival [157], 
nor did robust GDNF production in the spinal cord by   
genetically modified NPCs prevent muscle atrophy in SOD1 
rats [158]. These results underscore the need to define the range 
of signaling mechanisms governing the interaction between 
stem cells and the surrounding microenvironment to reach 
homeostasis by regulative mechanisms such as NTFs, other 
secreted molecules, and direct cell-to-cell communication 
(e.g.,  via  gap junctions). Better understanding of these   
processes will ultimately enable us to design combinatorial 
approaches with stem cell-mediated NTF therapy to tackle 
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  To the best of our knowledge, the only controlled ALS 
clinical trial with stem cells reported so far was performed in 
Italy [159], though there had been a few uncontrolled clinical 
studies with other growth factors, including peripheral injec-
tion, intraventricular infusion, or intrathecal injection of 
CNTF and BDNF [160,161]. In the phase 1 trial the effects 
of autologous bone marrow derived mesenchymal stem cells 
(MSCs) were transplanted safely in the thoracic spinal cord 
of 10 ALS patients [159], and no adverse effects were seen 
in the 24-month post-transplantation observation period. 
However, no significant changes in disease progression were 
observed. Based on recent findings in experimental animals, 
glial pathology in ALS should targeted in future trials [162]. 
For example, ALS model mice with conditionally deleted 
astrocytes expressing mutant hSOD1 showed delayed   
disease progression [163]. By introduction of stem cells with 
diversified capacities to express NTFs, such as GDNF, 
BDNF, IGF-I or VEGF, as well as forming direct cell-to-cell 
communications (e.g., via gap junctions) [8], motor neuron 
survival and function may be improved through modificaion 
of the tissue microenvironment [109,154].  
FUTURE DIRECTIONS  
Engineering NSCs as Transgene Carriers or Biopumps 
  It has been well established that NSCs constitutively   
produce a broad range of appropriately functioning peptidergic 
neurotrophic and neurite outgrowth-promoting factors [104]. 
To augment such capabilities further, NSCs have been   
engineered to express various transgenes, including NT-4/5, 
GDNF, BDNF, NGF, L1, sonic hedgehog, wnt-1, wnt-3a, as 
well as an assortment of biosynthetic and metabolic   
enzymes. Customized implantation of genetically engineered 
NSCs has been used to enhance neuronal differentiation, 
neurite outgrowth and connectivity within diseased tissue 
loci [108,109]. Also, NSCs have been manipulated to   
express the specific TrkC receptor of a neuron-inducing   
neurotrophin, NT-3 [33,77]. The engineered NSCs respond 
to NT-3 in an autocrine or paracrine fashion [33], which   
appears to trigger a significantly higher percentage of   
differentiating neurons in the TrkC-expressing NSCs group 
exposed to NT-3 than in the rAd-LacZ control cell group 
similarly exposed to NT-3 [33].  
  However, attempting to intervene in the natural expression 
of the various neurotrophic factors in their various proportions 
through genetic manipulation actually appeared to cause 
profile changes in trophic factor expression by the   
engineered cells [110]. For example, enhancing expression 
of NT-3 in a given clone of NSCs actually extinguished the 
clone’s expression of GDNF, replacing the promotion of 
motor axon ingrowth with an enhanced ingrowth of sensory 
axons [110]. Caution is called for when testing a therapeutic 
strategy based on transgene-mediated NTF overexpression   
in NSCs, for unintended effects may result from such   
(unanticipated) “disturbance” in post-engineering biological 
programs of the donor stem cells. The aforementioned facts, 
overall, suggest the feasibility of using bona fide NSCs or 
genetically engineered NSCs to serve as biopumps for a 
broad selection of biofactors when one is aiming to repair 
damaged or dysfunctional neural tissues. 
Induced Pluripotent Stem Cells (iPS Cells) 
  The past few years have seen the swift development in 
pluripotent stem cell technology led by the initiating report 
from the Yamanaka laboratory [165], in which a group of 
stemness- or mitosis-related transcription factor genes (Oct4, 
Sox2, Klf4 and c-Myc) were introduced to transform somatic 
cells dramatically into stem cell-like primitive entities with 
pluripotency and differentiation flexibility that are, to certain 
degrees, similar to ESCs. However, there are serious   
concerns regarding the safety of such iPSCs, especially the 
tumorigenic consequence, which currently prevents practical 
clinical use of iPS cells. Significant intrinsic variability in 
the derived iPSCs, abnormal expression of imprinted genes 
due to the random integration of transcription factors, persis-
tent donor gene expression, and difficulty in obtaining a   
sufficiently rapid cell multiplication rate in vitro to build up 
a cell population sufficient for use in human patients further 
limit the clinical use of these cells [165-167]. Therefore, 
additional molecular strategies using alterative gene   
targets [168,169], fewer targets [170-173], or viral vector-
free transfection technologies have been developed [175-
178], to circumvent the safety deficits of iPS cells before 
their therapeutic potential can be systematically examined. 
However, recent reports showed that patient-specific iPSCs 
can be generated for investigative studies on drug screening 
or for experimental therapy trials [179-181]. In addition, 
direct trans-differentiation of adult cell types has been   
presented as a further therapeutic option for reversing   
disease progression or transforming neighboring healthy 
cells to take over functions lost by diseased or dying cells 
[182]. Despite these advances, there appear to be no reports to 
date on NTF production by iPS cells, a pivotal parameter of 
stem cell biology [7], albeit there is recent important progress 
in the use of synthetic modified mRNA to increase efficiency 
of cell reprogramming and directed differentiation, as well  
as analyses of the impact of epigenetic memory on the   
molecular and functional properties of iPS cells [183-186]. 
A SUMMARY NOTE 
  Academia and the public have, in general, accepted the 
concept that stem cells provide an enormous opportunity to 
advance the understanding of developmental biology, and 
especially to develop novel clinical therapies. However, we 
still need refined knowledge on how NSCs can be crafted to 
deliver the range of NTFs that would meet the micro- 
environmental requirements to establish homeostasis that 
would offset an ongoing disease process. This ability of   
stem cells, buoyed by their innate developmental biological 
properties, may teach us how to mitigate the adverse side 
effects resulting from direct administration of NTFs one at a 
time. Complex diseases such as ALS, AD and Parkinson’s 
disease are especially likely to require complex solutions. 
NSCs, as described in this review, can interface and work 
synergistically with gene and growth factor therapy, gap 
junction-mediated homeostasis, anti-apoptotic and neuro- 
protective strategies, stimulation of neurogenesis, anti-
inflammatory and anti-scarring approaches, material science 
and tissue engineering, and at least in the case of SCI, with 
physical activity and exercise. Therefore, we propose an   
updated concept of NTF application. The traditional approach 580    Current Neuropharmacology, 2011, Vol. 9, No. 4  Teng et al. 
based on the pharmacological principles of trophic factor 
delivery (i.e., the dose and duration of administering a   
particular NTF), needs be revised to incorporate the newly 
appreciated importance of feedback-controlled production of 
trophic factors by the NSCs to mediate systemic homeostasis. 
Under this new conceptual context, we can begin to understand 
the wide spectrum of molecular tactics the NSCs deploy   
to regulate their trophic factor secretion at each normal   
developmental stage as they integrate into and prepare, mod-
ify, and guide the surrounding CNS environment towards the 
formation and homeostatic maintenance of a physiologically 
functioning adult nervous system. We believe that effectively 
adopting this conceptual view of “functional multipotency” 
of stem cells is essential for correct, efficient, and optimal use 
of trophic factors toward therapeutic goals (Fig. 1) [7,151].  
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